BioVie Inc. Files 8-K with Financials and Disclosures

TL;DR

BioVie Inc. dropped an 8-K on 9/25/24 covering financials and other events.

AI Summary

BioVie Inc. filed an 8-K on September 25, 2024, reporting on various events and financial statements. The company, formerly known as NanoAntibiotics, Inc., is incorporated in Nevada and operates in the Pharmaceutical Preparations sector. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

Why It Matters

This 8-K filing provides crucial updates and financial information for BioVie Inc., which is essential for investors to assess the company's current status and future prospects.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant corporate news, but the specific content here is primarily procedural and financial reporting, requiring further analysis of the detailed items.

Key Players & Entities

• BIOVIE INC. (company) — Registrant
• NANOANTIBIOTICS, INC. (company) — Former Company Name
• September 25, 2024 (date) — Date of Report
• Nevada (jurisdiction) — State of Incorporation
• 775-888-3162 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Marke
• $1.53 — at a combined public offering price of $1.53 per Share, or Pre-funded Warrant, and t
• $3,000,000, b — ny from the Offering were approximately $3,000,000, before deducting placement agent fees and
• $210,000 — and offering expenses of approximately $210,000. The Company intends to use the net pro
• $10.00 — he Exercise Price will be adjusted from $10.00 to $1.53, which was the price per share
• $1 — e Price will be adjusted from $10.00 to $1.53, which was the price per share of Co

Filing Documents

• bivi-20240925_8k.htm (8-K) — 30KB
• bivi-20240925_8kex99z1.htm (EX-99.1) — 9KB
• 0001520138-24-000320.txt ( ) — 213KB
• bivi-20240925.xsd (EX-101.SCH) — 3KB
• bivi-20240925_pre.xml (EX-101.PRE) — 22KB
• bivi-20240925_lab.xml (EX-101.LAB) — 33KB
• bivi-20240925_8k_htm.xml (XML) — 3KB

01Regulation FD Disclosure

Item 7.01Regulation FD Disclosure. On September 25, 2024, BioVie Inc. (the " Company ") issued a press release announcing the closing of the Offering (as defined below). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01Other Events

Item 8.01Other Events. Public Offering On September 25, 2024, the Company announced that it had closed the previously announced best efforts public offering (the " Offering ") of 1,360,800 shares (the " Shares ") of its class A common stock, par value $0.0001 per share (the " Common Stock "), pre-funded warrants (the " Pre-funded Warrants ") to purchase 600,000 shares of Common Stock, and warrants to purchase up to 1,960,800 shares of Common Stock (the " Common Warrants ") (CUSIP 09074F 140) at a combined public offering price of $1.53 per Share, or Pre-funded Warrant, and the associated Common Warrant. The gross proceeds to the Company from the Offering were approximately $3,000,000, before deducting placement agent fees and offering expenses of approximately $210,000. The Company intends to use the net proceeds from the Offering primarily for working capital and general corporate purposes. Acuitas Warrant On September 25, 2024, the Company notified Acuitas Group Holdings, LLC (" Acuitas ") of an adjustment to the exercise price (" Exercise Price ") of the warrant to purchase shares of Common Stock expiring July 15, 2028 (the " Acuitas Warrant ") that was issued by the Company to Acuitas pursuant to the Securities Purchase Agreement (the " SPA "), dated as of July 15, 2022, by and between the Company and Acuitas. Pursuant to Section 3(b) of the Acuitas Warrant, if the Company, at any time while the Acuitas Warrant is outstanding, issues shares of Common Stock at a price per share less than the Exercise Price, then the Exercise Price is reduced to such lower price per share. Accordingly, the Company gave notice to Acuitas that, effective at the close of business on September 25, 2024, the Exercise Price will be adjusted from $10.00 to $1.53, which was the price per share of Common Stock sold in the Offering. The foregoing descriptions of the SPA and Acuitas Warrant are not complete and are subject to and qualified in their entirety by reference to the full

Forward-Looking Statements

Forward-Looking Statements Certain of the statements made in this report are forward looking, such as those, among others, relating to the Company's expectations regarding the timing and completion of the Offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties related to completion of the public offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the Offering. More information about the risks and uncertainties faced by the Company is contained under the caption "Risk Factors" in the Company's prospectus supplement on Form 424B5 filed with the U.S. Securities and Exchange Commission on September 23, 2024. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

01Financial Statements and Exhibits

Item 9.01Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K/A filed with the SEC on July 18, 2022). 10.1 Securities Purchase Agreement, dated July 15, 2022, by and between the Company and Acuitas (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K/A filed with the SEC on July 18, 2022). 99.1 Press Release dated September 25, 2024. -2-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 25, 2024 BIOVIE INC. By: /s/ Joanne Wendy Kim Name: Joanne Wendy Kim Title: Chief Financial Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR